EOLS
Evolus Inc

3,839
Mkt Cap
$436.63M
Volume
357,933.00
52W High
$17.44
52W Low
$5.71
PE Ratio
-6.94
EOLS Fundamentals
Price
$6.75
Prev Close
$6.82
Open
$6.83
50D MA
$6.77
Beta
0.99
Avg. Volume
1.01M
EPS (Annual)
-$0.813
P/B
-23.39
Rev/Employee
$802,030.12
Loading...
Loading...
News
all
press releases
Evolus to Report Third Quarter Financial Results on November 5, 2025
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to...
Business Wire·13d ago
News Placeholder
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of -166.67% and -16.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd...
Business Wire·8mo ago
News Placeholder
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024...
Business Wire·8mo ago
News Placeholder
Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse Form...
Business Wire·8mo ago
News Placeholder
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an...
Business Wire·9mo ago
News Placeholder
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Companys Guidance
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and...
Business Wire·9mo ago

Latest EOLS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.